Lung cancer after lung transplantation: An analysis of 25 years of experience in a single institution

Chatron, Eva; Degot, T.; Salvaterra, Elena; Dumazet, Antoine; Porzio, Michele; Hirschi, Sandrine; Schüller, Arthur; Massard, Gilbert; Renaud-Picard, B.; Kessler, Romain

doi:10.1111/ctr.13446

Cited by 8 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been reported that the probability of accidental detection of LC in transplanted resected lungs is 0.8–2.2% ( 11 ), compared with a slightly higher proportion. Seven patients performed high-resolution CT screening before transplantation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The clinicopathological study of lung cancer concealed in end-stage of interstitial lung disease

Wang¹,

Zhang²,

Huang³

et al. 2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: Most of the patients with interstitial lung disease (ILD) complicated with lung cancer (ILD-LC) showed non-specific clinical manifestations. This study is to explore the incidence of lung cancer concealed in the end-stage of interstitial lung disease (LC-CES-ILD).Methods: A total of 154 cases of lung transplantation from March 2017 to December 2018 were studied retrospectively, of which 7 cases were found to be LC-CES-ILD. Serum tumor biomarkers were examined. HE and immunohistochemical staining were performed for the tumor tissue after the operation. Lung cancer (LC) drive gene was detected by quantitative real-time polymerase chain reaction (qRT-PCR).Results: The percentage of male patients with idiopathic pulmonary fibrosis (IPF) was 44.81%. The expression of all tumor biomarkers was significantly increased in 6 patients with LC-CES-ILD. After operation, apparent destruction of lung tissue structure was observed in 7 patients, and honeycomb appearance could be seen in some areas. After HE staining, 4 cases of acinar type and 2 cases of mucinous adenocarcinoma were found. The results of molecular pathology showed that only one case of mucinous adenocarcinoma had KRAS mutation, and no mutation of LC co-driving gene was found in the rest of the cases.Conclusions: It is necessary to detect the lung tissue of patients with end-stage ILD, which were probably correlated with the occurrence of LC concealed, before lung transplantation.

show abstract

Section: Discussionmentioning

confidence: 99%

“…It is the key to confirming ILC-CES-LC by careful naked eye observation of the diseased lungs resected in end-stage ILD transplantation. Adenocarcinoma was the most common histological type of ILD-LC, accounting for 43% ( 11 ), followed by squamous cell carcinoma. Most of our cases were adenocarcinoma.…”

Section: Discussionmentioning

confidence: 99%

The clinicopathological study of lung cancer concealed in end-stage of interstitial lung disease

Wang¹,

Zhang²,

Huang³

et al. 2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

show abstract

“…Incidental cancers at time of transplant have been found at a rate around 0.5-2.0% (Table 2) (13,19,20,(24)(25)(26)(27)(28)(29)(30).…”

Section: Incidental Cancers In Explantmentioning

confidence: 99%

“…Lung cancer found after transplant can develop in the native lung of single-lung recipients or in the lung allograft in single or double lung recipients. Tumors in the allograft may arise from an undetected primary or secondary malignancy from the donor at time of transplant or a new primary or secondary malignancy from the recipient after transplant (Table 3) (4,5,19,(24)(25)(26)28,(31)(32)(33)(34)(35)(36).…”

Section: New Lung Cancer After Transplantationmentioning

confidence: 99%

Lung cancer in lung transplant—management and outcomes

Rappaport¹,

Ahmad²

2022

Curr Chall Thorac Surg

View full text Add to dashboard Cite

Risk factors for lung cancer and end-stage lung disease significantly overlap, therefore index of suspicion for lung cancer should be high in lung transplant candidates. Thoracic surgeons can be faced with clinical scenarios where lung cancer can be discovered in the setting of lung transplant in three distinct categories: (I) transplant candidates who are known to have active or treated lung cancer, (II) transplant recipients who have unexpected incidental cancer discovered in their lung explant, and (III) transplant recipients who develop de novo lung cancer in the lung allograft or native lung after single-lung transplant. While previously considered "lung-limited" disease, bronchioloalveolar carcinoma (BAC) is no longer accepted as an indication for lung transplant due to poor outcomes with high recurrence rates and reclassification as invasive cancer. Any active lung cancer is considered a contraindication to transplant; however, if there is no evidence of disease after 5 years of definitive therapy, lung transplant can be offered. Indeterminate pulmonary nodules are common in lung transplant candidates and should be evaluated in a multidisciplinary fashion. Incidental lung cancer found in explanted lungs portends poor survival. De novo lung cancer after transplant is more common in the native lung after single-lung transplant. Cancer that develops in the allograft can be treated with definitive local therapies and systemic therapies, but long term survival has not yet been demonstrated.

show abstract

“…Некоторые терминальные стадии заболеваний, по поводу которых осуществляется трансплантация легких, например хроническая обструктивная болезнь легких (ХОБЛ) и фиброз легких, также предполагают повышенный риск развития рака легкого при однолегочной трансплантации в сравнении с двулегочной. Большинство авторов говорит о возрастании риска развития рака легкого почти вдвое после 60 лет [8,14,[17][18][19][20][21].…”

Section: патогенез и факторы рискаunclassified

Lung cancer in solid organ transplant recipients

Nikulin

Пашков

Yakunin

2021

RJTAO

View full text Add to dashboard Cite

Lung cancer remains the leading cause of cancer mortality worldwide. Solid organ transplant recipients are at risk of developing malignant tumors, including lung cancer, due to long-term use of immunosuppressive drugs. Development of cancer, including lung cancer, in this patient cohort, has a number of peculiarities. Moreover, malignant tumors in these patients are difficult to treat and have a poorer prognosis. This review presents a study of the issues concerning the mechanisms of lung cancer development, screening methods and treatment in solid organ transplant recipients.

show abstract

Lung cancer after lung transplantation: An analysis of 25 years of experience in a single institution

Cited by 8 publications

References 25 publications

The clinicopathological study of lung cancer concealed in end-stage of interstitial lung disease

The clinicopathological study of lung cancer concealed in end-stage of interstitial lung disease

Lung cancer in lung transplant—management and outcomes

Lung cancer in solid organ transplant recipients

Contact Info

Product

Resources

About